Literature DB >> 10378897

Changes in signal transduction downstream from the granulocyte-macrophage colony-stimulating factor receptor during differentiation of primary hemopoietic cells.

H Wheadon1, P J Roberts, M J Watts, D C Linch.   

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multifunctional cytokine, having different effects on primitive hemopoietic cells and terminally differentiated end-cells of the myeloid lineage. Human primitive hemopoietic cells (CD34+) were obtained from the peripheral blood after mobilization and induced to proliferate and then differentiate with a combination of cytokines in vitro. Cells at different time points were then used to analyze the expression of the GM-CSF receptor and GM-CSF mediated activation of the JAK 2-STAT 5 and MAP kinase pathways. Scatchard analysis as measured by radioligand binding revealed that freshly purified CD34+ cells expressed 36+/-1 high affinity receptors per cell (mean +/- SE, n = 3) and the level of expression was not significantly different after 3 days in culture, but rose five- to tenfold by day 8. The day 0 CD34+ cells were hyporesponsive to GM-CSF, but by 3 days in culture the cells were still morphologically immature but were actively proliferating and exhibited maximal GM-CSF induced JAK 2-STAT 5 and MAP kinase activation at the optimal time point. Further culture of the CD34+ cells resulted in myeloid differentiation associated with prolongation of MAP kinase activation but not JAK 2-STAT 5 activation. These data indicate that the JAK 2-STAT 5 and MAP kinase pathways are independently regulated and that changes in these signaling pathways occur with differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10378897     DOI: 10.1016/s0301-472x(99)00041-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  4 in total

1.  Growth hormone protects human lymphocytes from irradiation-induced cell death.

Authors:  Laurence Lempereur; Daria Brambilla; Giovanna Maria Scoto; Maria D'Alcamo; Vincent Goffin; Lucia Crosta; Tullio Palmucci; Liborio Rampello; Renato Bernardini; Giuseppina Cantarella
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

2.  Human immunodeficiency virus type 1 infection inhibits granulocyte-macrophage colony-stimulating factor-induced activation of STAT5A in human monocyte-derived macrophages.

Authors:  Tammra J Warby; Suzanne M Crowe; Anthony Jaworowski
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.

Authors:  Seiichi Okabe; Tetsuzo Tauchi; Seiichiro Katagiri; Yuko Tanaka; Kazuma Ohyashiki
Journal:  J Hematol Oncol       Date:  2014-04-28       Impact factor: 17.388

4.  Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.

Authors:  Weiguo Zhang; Charlie Ly; Jo Ishizawa; Hong Mu; Vivian Ruvolo; Sharon Shacham; Naval Daver; Michael Andreeff
Journal:  Haematologica       Date:  2018-05-17       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.